ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)

被引：1
|
作者：
Rathkopf, Dana E. [1 ]
Antonarakis, Emmanuel S. [2 ]
Shore, Neal D. [3 ]
Tutrone, Ronald [4 ]
Alumkal, Joshi J. [5 ]
Ryan, Charles J. [6 ]
Saleh, Mansoor N. [7 ]
Hauke, Ralph J. [8 ]
Bandekar, Rajesh [9 ]
Maneval, Edna Chow [10 ]
de Boer, Carla [11 ]
Todd, Mary [12 ]
Yu, Margaret K. [13 ]
Scher, Howard I. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Chesapeake Urol Res Associates, Baltimore, MD USA
[5] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[6] USCF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[7] Georgia Canc Specialists PC, Sandy Springs, GA USA
[8] Nebraska Canc Specialists, Omaha, NE USA
[9] Janssen Res & Dev, Philadelphia, PA USA
[10] Aragon Pharmaceut, San Diego, CA USA
[11] Janssen Biol BV, Leiden, Netherlands
[12] Janssen Global Serv, Raritan, NJ USA
[13] Janssen Res & Dev, Los Angeles, CA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT239
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Posadas, Edwin M.
    Chit, Kim N.
    de Wit, Ronald
    de Jonge, Maja J. A.
    Attard, Gerhardt
    Friedlander, Terence
    Yu, Margaret
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene
    Gonzalez, Martha
    Trudel, Geralyn C.
    Chauhan, Vijay
    Saad, Fred
    [J]. CANCER RESEARCH, 2015, 75
  • [4] Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    Yu, Margaret K.
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene Connelly
    Gonzalez, Martha
    Trudel, Geralyn Carol
    Chauhan, Vijay
    Jiao, Juhui James
    Saad, Fred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] ARN-509 IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Rathkopf, D.
    Antonarakis, E. S.
    Shore, N. D.
    Tutrone, R.
    Alumkal, J.
    Ryan, C. J.
    Saleh, M.
    Hauke, R.
    Chow-Maneval, E.
    Scher, H. I.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 317 - 317
  • [6] Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla J.
    Yu, Margaret K.
    Scher, Howard I.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3544 - 3551
  • [7] A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Morris, Michael J.
    Danila, Daniel Costin
    Slovin, Susan F.
    Steinbrecher, Jill Elise
    Arauz, Gabrielle
    Curley, Tracy
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Fleisher, Martin
    Landa, Jonathan
    Fox, Josef J.
    Larson, Steven M.
    Scher, Howard I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] ARN-509 IS SAFE AND EFFECTIVE IN CASTRATION-RESISTANT PROSTATE CANCER
    不详
    [J]. CANCER DISCOVERY, 2013, 3 (10) : 1093 - 1093
  • [9] A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
    Rathkopf, Dana E.
    Attard, Gerhardt
    Efstathiou, Eleni
    Yu, Margaret K.
    Griffin, Thomas W.
    Todd, Mary Beth
    Wu, Daphne
    Kheoh, Thian
    Zhao, Xin
    Saad, Fred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Smith, M. R.
    Antonarakis, E. S.
    Ryan, C. J.
    Berry, W.
    Shore, N. D.
    Liu, G.
    Alumkal, J.
    Higano, C.
    Chow-Maneval, E.
    Rathkopf, D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 303 - 303
12345